B. Braun Receives Medicare Payment Approval for Peripheral Nerve Block Devices; FDA Approves Providence Medical’s CORUS PCSS 3D-T Spinal Device; PurMinds Enters Clinical Validation Collaboration with SpectroChip and Taiwan-Based Hospital; MemorialCare Leads South Los Angeles County in Robotic-Assisted Shoulder Replacement Technology; Clinical Study Demonstrates the Potential of Home-Based Diuretic Delivery for Heart Failure; VIVA 2026 Highlights New Clinical Trial Results

B. Braun Peripheral Nerve Block Devices Approved for Separate Medicare Payment Under the NOPAIN Act 

On 14 October 2026, B. Braun Medical announced that the U.S. Centers for Medicare and Medicaid Services had approved its Stimuplex Single-Shot Nerve Block Needles as qualifying non-opioid medical devices under the NOPAIN Act, with eligibility effective April 30, 2026. The policy allowed qualifying devices used for postsurgical pain relief to receive temporary separate Medicare payments in hospital outpatient departments and ambulatory surgical centers. The needles were designed for single-injection peripheral nerve blocks performed during regional anesthesia procedures, supporting pain management while helping reduce reliance on opioid medications. The reimbursement decision improved the financial framework for eligible facilities using these devices and highlighted the growing role of non-opioid approaches in postsurgical pain control. The policy was scheduled to remain in effect through December 31, 2027, unless extended by Congress.

“The inclusion of these B. Braun peripheral nerve block devices under the NOPAIN Act reflects the important role enabling technologies play in supporting multimodal, opioid-sparing pain management strategies,” said Kristin Brown, Director, Pain Control Marketing, B. Braun Medical Inc.

As per DelveInsight’s “Pain Management Devices Market Report,” the pain management devices market is estimated at USD 5.67 billion in 2025 and is projected to reach USD 10.9 billion by 2034. Growth is anchored in the rising global burden of chronic pain, the shift toward non-opioid and opioid-sparing therapies, and continued innovation in neurostimulation, ablation, and targeted drug delivery technologies. The global Pain Management Devices market is growing at a CAGR of 7.5% during the forecast period from 2026 to 2034. Pain management devices are medical technologies used to treat acute and chronic pain through non-pharmacological or device-delivered mechanisms, offering alternatives and complements to opioid and other systemic medications. The category spans electrical stimulation devices, including implantable neurostimulation systems such as spinal cord, deep brain, and sacral nerve stimulators and non-invasive transcutaneous electrical nerve stimulation; analgesic infusion pumps, including implantable intrathecal pumps and external patient-controlled analgesia pumps; and ablation devices that use radiofrequency or cryogenic energy to interrupt pain signaling. These technologies are applied across musculoskeletal, cancer, neuropathic, and other pain conditions and are delivered in hospitals, specialty and interventional pain clinics, rehabilitation centers, and home settings. Over the past decade, the field has advanced from open-loop stimulation and conventional pumps toward closed-loop and high-frequency neurostimulation, miniaturized implants, and image-guided ablation, positioning pain management devices as central tools in interventional and opioid-sparing pain care across healthcare settings worldwide.

FDA Approved Providence Medical’s CORUS PCSS 3D-T Spinal Device

On 13 October 2026, Providence Medical Technology announced that it had received FDA 510(k) clearance for its CORUS Posterior Cervical Stabilization System 3D-T. The next-generation implant combined a 3D-manufactured porous titanium structure with an established posterior cervical stabilization design to support bone ingrowth and spinal fusion. The device was intended to immobilize and stabilize spinal segments as an adjunct to posterior cervical fusion in patients with cervical degenerative disc disease. Its design incorporated integrated screw fixation and was developed to support fusion procedures involving the cervical spine. The company planned to showcase the system at the North American Spine Society’s 2026 Annual Meeting in San Antonio, Texas. The regulatory clearance strengthened Providence Medical Technology’s spinal implant portfolio and highlighted continued innovation in cervical stabilization, implant design, and surgical treatment for degenerative spinal conditions.

As per DelveInsight’s “Spinal Implants Market Report,” The global spinal implants market was valued at USD 14,324.12 million in 2024, growing at a CAGR of 5.50% during the forecast period from 2025 to 2032 to reach USD 21,899.24 million by 2032. The rising cases of spinal disorders particularly among aging populations have significantly increased the demand for corrective surgical interventions. Simultaneously, the surge in sports-related and accident-induced spinal injuries is fueling the need for advanced implantable solutions. Moreover, there is a growing preference for non-fusion and motion preservation devices that maintain spinal mobility and enhance patient outcomes, especially among younger and more active individuals. Coupled with this is the uptick in product development activities and technological innovations by key market players globally, which is expanding the range of available solutions and improving surgical success rates. Together, these trends are accelerating the adoption of Spinal Implants and driving the overall market during the forecast period from 2025 to 2032.

PurMinds Announced Clinical Validation Collaboration with SpectroChip and Taiwan’s Kaohsiung Municipal Siaogang Hospital 

On 14 October 2026, PurMinds Enterprises announced a five-year collaboration with SpectroChip and Taiwan’s Kaohsiung Municipal Siaogang Hospital to advance research, education, and clinical validation of point-of-care diagnostic technologies. The collaboration combined SpectroChip’s photonic-chip-based portable testing technology, PurMinds’ SwiftLab platform and precision medicine solutions, and the hospital’s clinical research capabilities. The partners planned to establish a joint clinical validation framework to evaluate diagnostic performance, assess testing workflows, and investigate potential clinical applications, subject to relevant ethical and regulatory approvals. SpectroChip also committed NT$3 million in research and educational funding to the hospital over five years. The collaboration was expected to support the evaluation and potential commercialization of portable quantitative diagnostic solutions, creating opportunities in point-of-care testing, rapid diagnostics, and precision medicine.

“This collaboration brings together SpectroChip’s cutting-edge photonic chip technology, Siaogang Hospital’s clinical research environment and PurMinds’ precision-medicine platform and commercialization strategy,” said Janet Qi, Founder and Chief Executive Officer of PurMinds.  “Given the full-spectrum spectrometry embedded in our platform and its potential to develop an extended catalog of testing items, our vision is to connect with clinically relevant testing applications and the research needed to evaluate them.”

“For over two decades, our team has worked to miniaturize spectrometer technology and make quantitative analysis possible through our proprietary photonic chip technology. This collaboration with PurMinds and Siaogang Hospital represents an important opportunity to bring our technology into a structured clinical research environment, where diagnostic performance and testing workflows can be systematically evaluated,” said Dr. Cheng-Hao (Kevin) Ko, founder of SpectroChip and inventor of the SwiftLab Platform.

As per DelveInsight’s “Point of Care Diagnostics Market Report,” the global point of care diagnostics market is estimated to grow at a CAGR of 6.61% during the forecast period from 2025 to 2032. The demand for point of care diagnostics is primarily being boosted by the increasing patient population suffering from various lifestyle disorders such as diabetes and cardiovascular diseases among others, the rising prevalence of infectious diseases, growing awareness regarding health and disease-free life, and innovation in product development among others, thereby contributing to the overall growth of the point of care diagnostics market during the forecast period from 2025-2032.

On 14 October 2026, MemorialCare Orthopedic & Spine Institute at Long Beach Medical Center announced the successful completion of its first robotic-assisted shoulder replacement procedure using Zimmer Biomet’s ROSA Shoulder System. The introduction made the hospital the first in South Los Angeles County to offer this technology. The system used patient CT scans to generate three-dimensional shoulder models for preoperative planning and provided real-time robotic navigation to help surgeons assess implant positioning during surgery. It supported both anatomical and reverse shoulder replacement procedures, with applications for patients experiencing bone loss, deformities, and other complex shoulder conditions. The technology was designed to improve surgical planning and implant placement accuracy while allowing surgeons to retain control of the procedure. Its introduction expanded access to advanced orthopedic treatment and highlighted opportunities for robotic technologies in shoulder arthroplasty and joint reconstruction.

“The ROSA Shoulder System brings a new level of precision to shoulder replacement surgery,” said Shahryar Ahmadi, M.D., orthopedic surgeon, MemorialCare Orthopedic & Spine Institute, Long Beach Medical Center. “Its real-time feedback and advanced planning capabilities allow us to tailor procedures to each patient’s unique anatomy and position implants more accurately. That level of precision can help improve outcomes, support recovery and give patients greater confidence in their results.”

“Retrospective analysis found substantial rates of malpositioning of glenoid and humeral components in conventional and reverse shoulder arthroplasty,” Dr. Ahmadi said. “While the surgeon remains in control, ROSA’s assistance with glenoid reaming and humeral resection enhances our ability to plan and execute each step with greater precision.”

According to DelveInsight’s “Shoulder Replacement Devices Market Report”, the shoulder replacement devices market was valued at USD 1.68 billion in 2023, growing at a CAGR of 7.27% during the forecast period from 2024 to 2030, to reach USD 2.54 billion by 2030. The shoulder replacement devices market is experiencing significant growth owing to the widespread instances of shoulder injuries and degenerative conditions like osteoarthritis and rheumatoid arthritis, the rise in product development & innovation activities, among others that are acting as key factors, contributing to the market growth of the shoulder replacement devices market during the forecast period from 2024 to 2030.

Trial Demonstrates Feasibility of at-Home Subcutaneous Diuretic Therapy for Heart Failure-Associated Edema

On 14 October 2026, SQ Innovation announced the publication of results from its SUBCUT HF II clinical trial in the Journal of the American College of Cardiology. The study evaluated Lasix ONYU, a subcutaneous furosemide drug-device combination designed to enable patients with chronic heart failure to receive diuretic treatment at home. The multicenter randomized trial involved 172 patients across 20 hospitals in the United Kingdom and compared home-based treatment with conventional inpatient intravenous diuretic therapy. The results showed that patients receiving home treatment experienced an average of four additional days alive and outside the hospital within 30 days, while their initial hospital stays were shortened by an average of 5.5 days. Serious adverse events occurred at comparable rates between the treatment groups. The findings supported the feasibility of home-administered subcutaneous diuretic therapy and highlighted its potential to reduce hospitalization burdens while expanding treatment options for patients with heart failure-associated edema.

“The conclusion that a diuretic treatment at home can replace conventional IV treatment in a hospital rest on two pillars: demonstrating that it can induce equivalent diuresis and that patients can safely self-administer a hospital-equivalent dose at home,” said Pieter Muntendam, MD, Founder, President and CEO of SQ Innovation. “Previous studies conclusively reported the former, and this study provides evidence for the latter. Patients self-administered approximately 900 mg of furosemide over the course of treatment comparable to what a patient may receive during a hospital admission with similar treatment outcomes.”

As per DelveInsight’s “Congestive Heart Failure Treatment Devices Market Report,” the congestive heart failure (CHF) treatment devices market was valued at USD 17.41 billion in 2023, growing at a CAGR of 8.26% during the forecast period from 2024 to 2030 to reach USD 27.96 billion by 2030. The congestive heart failure (CHF) treatment devices market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), innovative product developmental activities by regulatory bodies, and the rising geriatric population that is expected to escalate the overall growth of the congestive heart failure (CHF) treatment devices market during the forecast period from 2024 to 2030.

Late-Breaking Clinical Trial Results Announced at VIVA 2026 

On 14 October 2026, VIVA Foundation announced late-breaking clinical trial results at the VIVA 2026 conference in Las Vegas, highlighting advances in the treatment of peripheral artery disease (PAD), chronic limb-threatening ischemia, and pulmonary embolism. The studies evaluated several vascular treatment technologies, including sirolimus-eluting drug-coated balloons, drug-eluting resorbable scaffolds, intravascular lithotripsy systems, covered stents, and mechanical thrombectomy devices. Findings from the SELUTION4SFA trial showed that the SELUTION SLR drug-eluting balloon achieved superior efficacy compared with conventional balloon angioplasty, with 12-month primary patency rates of 90.3% and 79.4%, respectively. Other studies reported encouraging outcomes in reducing repeat revascularization, maintaining vessel patency, improving wound healing, and preserving limbs in patients with complex vascular conditions. Clinical findings also supported continued evaluation of catheter-directed thrombolysis and mechanical thrombectomy for pulmonary embolism. Overall, the results highlighted ongoing innovation in minimally invasive vascular interventions and supported further development of advanced devices and treatment approaches for peripheral vascular diseases.

According to DelveInsight’s “Peripheral Artery Disease (PAD) Treatment Market Report,” the peripheral artery disease (PAD) market was valued at USD 3,757.64 million in 2023, growing at a CAGR of 6.64% during the forecast period from 2024 to 2030 to reach USD 5,469.02 million by 2030. The demand for Peripheral Artery Disease (PAD) is primarily being boosted owing to the rising prevalence of peripheral artery disease & arteriosclerosis, the rising prevalence of obesity, diabetes, and high blood pressure, the growing burden of the elderly population, the rising demand for minimally invasive procedures, among others during the forecast period from 2024 to 2030.